Luxturna Approved In EU: Novartis Outlines Lessons For Gene Therapy Strategies
The European Commission has officially approved Luxturna, Novartis/Spark Therapeutics’ transformative gene therapy. The Swiss firm tells Scrip how the lessons it expects to learn from launching its first gene therapy will inform its future strategy in this new field.
